Search results
Order by most recent / most popular / relevance
Results: 1-10 of 19
Personalized medicine and the gene patenting debate
- Foley & Lardner LLP
- -
- USA
- -
- April 15 2013
The transcript for today's Supreme Court oral argument in The Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (2013) has
Federal Circuit reaffirms patent eligibility of personalized medicine and diagnostic method claims
- Foley & Lardner LLP
- -
- USA
- -
- December 17 2010
Today, in Prometheus Laboratories, Inc. v. Mayo Collaborative Services, No. 2008-1403 (Fed. Cir. 2010), the Federal Circuit affirmed that personalized medicine and medical diagnostic claims are not per se unpatentable for claiming natural phenomena
Supreme Court grants certiorari in Prometheus v. Mayo (again)
- Foley & Lardner LLP
- -
- USA
- -
- June 20 2011
On June 20, 2011, the United States Supreme Court granted Mayo's petition for certiorari in Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 628 F.3d 1347 (Fed. Cir. 2010), a case addressing patent eligibility under 35 U.S.C. 101 of certain method claims relevant to personalized medicine
Gene patents and diagnostics: the economics of innovation
- Foley & Lardner LLP
- -
- USA
- -
- June 11 2012
The increasing importance of genetic markers and diagnostic tests in the drug approval process and the delivery of health care requires consideration of who will underwrite the necessary research and development, Michael Hopkins and Stuart Hogarth argue in the recent issue of Nature Biotechnology
Patenting business methods after Mayo
- Foley & Lardner LLP
- -
- USA
- -
- July 30 2012
Advances in information technology, such as high-performance computing, enables the collection, analysis and sharing of information between patients and medical providers
Amici urge reversal of “gene patenting” decision
- Foley & Lardner LLP
- -
- USA
- -
- November 29 2012
On November 30th, 2012, the U.S. Supreme Court will conference and consider whether to review the patent-eligibility of isolated DNA sequences
Personalized medicine after the ACLU "gene patenting" decision
- Foley & Lardner LLP
- -
- USA
- -
- August 20 2012
The biotechnology industry, including those investing in personalized medicine, have been waiting for the Federal Circuit’s decision that answers the questions whether isolated DNA and use of the isolated material are patent-eligible under 35 U.S.C. 101
Are human genes patentable?
- Foley & Lardner LLP
- -
- USA
- -
- December 11 2012
As reported in my November 30th, 2012 post, the U.S. Supreme Court granted certiorari to review the issue “are human genes patentable?”
Patent pool simplifies development of personalized medicine
- Foley & Lardner LLP
- -
- USA
- -
- September 28 2012
One argument often cited against patenting is that multiple patents can cover one product, its preparation and use, creating a so-called “patent thicket” that must be unwound like a bowl of spaghetti before a new technology is free of potential liability
Genetic data, patents and trade secrets
- Foley & Lardner LLP
- -
- USA
- -
- November 9 2012
Patents protect proprietary information but are of limited duration
Current Search
- Workarea - Healthcare
- Workarea - Patents
- Firm Name - Foley & Lardner LLP
- Author - Antoinette F. Konski